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Abstract 
Purpose: The aims of this study were to comprehensively describe the psychosocial and medical characteristics of 
women who initiated tamoxifen or aromatase inhibitors for breast cancer and to compare levels of emotional distress 
according to their medical (tumor demographics, treatment type, treatment duration) and psychosocial (self-esteem, 
perceived social support, sociodemographic) characteristics.
Methods: A total of 104 women currently receiving tamoxifen or aromatase inhibitors was recruited from outpa-
tient clinics and they were asked to complete self-report questionnaires including the Rosenberg Self-Esteem Scale, 
the Multidimensional Scale of Perceived Social Support and the Hospital Anxiety and Depression Scale during their 
routine follow-up. Psychosocial and medical characteristics of the patients were first described and subsequently the 
score of emotional distress was compared with these.
Results: The patients’ mean age was 52.49 ± 10.30 and they were being treated for an average of 24.3 months. Out 
of the patients’ characteristics, educational and marital status, level of perceived social support and self-esteem were 
all significantly related with emotional distress. As for medical variables, the score of distress was relatively higher 
among patients in the first 2 years of their treatment than the patients who were in the second to fifth years of treat-
ment, but this was not statistically significant.
Conclusions: Given the results of this study, it appeared that patient variables, rather than the medical or treatment 
characteristics, were related with emotional distress in women undergoing endocrine treatment. For that reason it is 
critical that medical staff are aware of patient factors that relate to distress during a long period of adjuvant endocrine 
therapy.
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Background
Breast cancer is a major public health problem that 
affects women in many parts of the world as well as 
Turkey (Ferlay et al. 2015). Breast cancer treatments have 
substantially improved over the past two decades, which 
have led to a reduction in breast cancer mortality due to 
both screening and improvements in therapy (Berry et al. 
2005).
Approximately 70  % of all breast cancers are hor-
mone receptor positive (Harvey et  al. 1999) and in this 
group of patients, upon completion of primary therapy 
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(e.g., surgery, radiation, chemotherapy), adjuvant endo-
crine therapy (AET) with either tamoxifen or aromatase 
inhibitors (AIs) is an important component (Early Breast 
Cancer Trialists’ Collaborative Group 2005). The widely 
accepted standard for AET for hormone receptor positive 
breast lesions for many years was the administration of 
tamoxifen for the duration of 5 years (Howell et al. 2005). 
However with the development of the third-generation 
AIs (i.e. anastrozole, letrozole and exemestane) the use 
of tamoxifen was replaced in postmenopausal patients 
(Smith and Dowsett 2003). A lot of studies indicated that 
both regimens, tamoxifen and AIs, are appropriate treat-
ment options in these patients as they reduce risk of dis-
ease relapse and death (Burstein et al. 2014; Regan et al. 
2011).
Although AET can improve disease-free survival in 
breast cancer patients, some studies indicated that it 
is associated with considerable side effects that nega-
tively impact women’s well-being (von Blanckenburg 
et  al. 2013). During AET, many breast cancer patients 
can experience a range of physical and psychological 
side effects such as hot flushes, joint pain and emotional 
distress (ED) (Rosenberg et  al. 2015; van Londen et  al. 
2014; Bower 2008). Distress is a multifactorial unpleas-
ant emotional experience of a psychological, social and/
or spiritual nature that may interfere with the ability to 
cope effectively with cancer, its symptoms and its physi-
cal treatment (National Comprehensive Cancer Network 
2011). While most of the previous studies focused on 
the physical adverse effects in women taking AET, very 
few studies addressed the emotional problems such as 
anxiety and depression among these patients (Rosenberg 
et al. 2015). From these limited studies, Ploos van Amstel 
et al. 2013 conducted research among breast cancer sur-
vivors of whom 37  % were still treated with hormonal 
therapy and showed that one-third of all cancer survivors 
experienced distress. However in a different study, it was 
reported that depression scores were within the normal 
range in patients treated with tamoxifen or raloxifene in 
comparison to healthy women in similar age group (Land 
et al. 2006). More specifically, Schilder et al. (2009) evalu-
ated symptoms of depression in breast cancer patients 
treated with tamoxifen or exemestane and healthy con-
trol groups and researchers indicated that there were no 
differences between patients and control groups with 
regard to mental health or depressive symptoms.
The objectives of our cross-sectional study were to 
describe comprehensively the psychosocial charac-
teristics of patients and to investigate the relationship 
between psychosocial and medical characteristics and 
self-reported ED in women with breast cancer who are 
on tamoxifen or aromatase inhibitors. Knowledge about 
this relationship is fundamental to develop necessary 
interventions to reduce ED in women during the long 
treatment journey. Psychosocial factors were assessed 
by evaluating self-esteem, perceived social support and 
patients’ sociodemographic characteristics including age, 
marital status, number of children, level of education, 
socioeconomic status, body mass index and menopausal 
status at diagnosis. Illness and treatment-related factors 
were assessed by evaluating a broad range of medical fac-
tors such as type and duration of AET, type of surgery, 
tumor stage and grade, and administration of chemo-
therapy or radiotherapy. Most of the included medical 
and psychosocial parameters in this study have not been 
investigated in previous studies.
Methods
Patients
We employed a cross-sectional, descriptive, and correla-
tional design. Participants were recruited consecutively 
between September 2015 and December 2015 during 
their routine outpatient clinic visits in Hacettepe Uni-
versity, Institute of Oncology. Patients were considered 
eligible for participation if they were diagnosed with 
non-metastatic (stages I–III) hormone receptor-positive 
breast cancer, had completed their surgical treatment, 
chemotherapy, and/or radiation therapy and were cur-
rently taking adjuvant endocrine therapy (tamoxifen 
or AIs) for at least 1  month. All included patients were 
female, older than 18  years of age and had graduated 
from primary school or higher. Patients were excluded if 
they were taking AET as part of treatment for metastatic 
disease or had documented psychiatric or neurological 
disorders that could interfere with study participation 
(e.g., dementia or schizophrenia).
Of the 130 women approached, 87  % agreed to par-
ticipate. A further nine agreed participants had to be 
excluded due to the following reasons: 4 women took 
AET for less than 1  month and 5 women did not com-
plete the study questionnaire despite their consent. 104 
women were included in the final analysis.
Study protocol
The study was approved by the ethical committee of 
the Hacettepe University, Faculty of Medicine. The 
researcher and medical oncologists read relevant medi-
cal records to search for potential patients in order to 
decide patients’ eligibility for this study. Patients who 
passed this pre-screening were informed and the purpose 
of the study was explained to them by their oncologists 
at the time of routine medical follow-up. When patients 
agreed to participate in the study, they were contacted by 
the study research assistant who provided further infor-
mation. They were informed that their involvement was 
voluntary and they could withdraw from the study any 
Page 3 of 7Ates et al. SpringerPlus  (2016) 5:486 
time without affecting their care. After written and verbal 
informed consent was obtained from each participant, 
data regarding their age, educational and marital status, 
number of children, and socioeconomic status was asked 
during face-to-face interviews using a demographic ques-
tionnaire. Subsequently, patients completed self-report 
questionnaires. If possible, we requested patients to 
complete the questionnaire without assistance and sup-
port was given only when it was necessary. The medical 
information including tumor stage and grade, menopau-
sal status, type of surgery, type and duration of AET, and 
administration of chemotherapy and/or radiotherapy was 
obtained from medical records.
Questionnaires
Demographic and Clinical Questionnaire
The sociodemographic information of the patients is 
listed in Table 1 and, as indicated above, was obtained by 
interview, while cancer and treatment related data was 
abstracted from the patients’ medical charts. Patients’ 
height and weight measurements were collected from 
medical charts and used to calculate body mass index 
(BMI). BMI was calculated by dividing body weight (in 
kilograms) by the square of height in meters (kg/m2).
Hospital Anxiety and Depression Scale (HADs)
This is a self-reported scale originally developed to indi-
cate the possible presence of anxiety and depression 
states (Zigmond and Snaith 1983). It contains two sub-
scales (one for anxiety and the one for depression) and 
14 items. Total scores for each subscale range from 0 to 
21, and higher scores represent greater anxiety or depres-
sion. The Turkish version of this scale was assessed 
by Aydemir et  al. (1997) for its validity and reliability 
(Aydemir et  al. 1997). Aydemir et  al. (1997) stated that 
the Cronbach alpha was 0.85 and 0.77 for anxiety and 
depression subscales respectively. In this study the Cron-
bach alpha was 0.84 in the anxiety subscale and 0.80 in 
the depression subscale.
While the HADs scale is accepted as valid and reliable 
in cancer patients and is used frequently as a standard in 
the field of clinical oncology/psychology services (Voder-
maier and Millman 2011), recent studies have indicated 
that it does not provide a good separation between 
Table 1 Socio-demographic and medical characteristics of patients (n = 104)
a Includes single, divorced, separated, widower
b 2 patients used aromatase inhibitors then switched tamoxifen
c AIs includes anastrozole and letrozole; 4 patients used tamoxifen then switched to AIs
Patient factors % (n) Cancer and treatment factors % (n)
Age [mean (min–max)] 52.49 (32–77) Time (months) since AET initiation 24.38 (1–58)
Marital status Between 1 and 24 months 49 (51)
 Married 75.9 (79) Between 25 and 58 months 51 (53)
 Singlea 24 (25) Current treatment
Children Tamoxifenb 47.1 (49)
 One or more 82.7 (86) Aromatase inhibitors (AIs)c 52.9 (55)
 None 17.3 (18) Radiotherapy
Educational level Yes 71.2 (74)
 Primary or secondary school 33.7 (35) No 28.8 (30)
 High school 32.7 (34) Chemotherapy
 College or above 33.7 (35) Yes 61.5 (64)
Socioeconomic status No 38.5 (40)
 Low 17.3 (18) Pathological tumor stage
 Middle 70.2 (73) T1 40.4 (42)
 High 12.5 (13) T2 51 (53)
Body mass index (kg/m2) T3 8.7 (9)
 ≤ 24.9 31.7 (33) Histological grade
 25–29.9 40.4 (42) Grade I 11.5 (12)
 ≥30 27.9 (29) Grade II 49 (51)
Menopausal status Grade III 39.4 (41)
 Pre-menopausal 46.2 (48) Type of surgery
 Peri or post-menopausal 53.8 (56) Mastectomy 56.7 (59)
Breast conserving surgery 43.3 (45)
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symptoms of anxiety and depression (Norton et al. 2013). 
However it is effective in measuring the level of emo-
tional distress (Norton et al. 2013; Cosco et al. 2012). For 
that reason we decided to use the ‘HADs Total’ in emo-
tional distress calculations.
Multidimensional Scale of Perceived Social Support 
(MSPSS)
The MSPSS was used to measure the level of perceived 
social support from family, friends, and significant oth-
ers. It contains 12 items and each item is rated on a 7 
point scale. (Zimet et al. 1988). All items are added and 
then divided by 12 for the total score. High scores indi-
cate a high degree of perceived social support. Its valid-
ity and reliability in Turkey was performed by Eker and 
Arkar (1995) and the Cronbach alpha was 0.89 (Eker and 
Arkar 1995). In this this study the Cronbach alpha was 
found to be 0.88.
Rosenberg Self‑Esteem Scale (RSES)
This scale measures global self-esteem with a 10-item 
scale based on direct self-reporting (Rosenberg 1965). 
Possible scores of the scale range from 10 to 40. Higher 
scores represent more positive attitudes toward the 
self. This scale was adapted to the Turkish population 
by Cuhadaroglu (1986) and the correlation between the 
scale and psychiatric interview results was found to be 
0.71 and the test–retest reliability was reported as 0.75 
(Cuhadaroglu 1986). For the present study, the Cronbach 
alpha of the scale was 0.85.
Statistical analysis
Based on the previous studies, we divided the total 
patients into two groups: Group one comprised patients 
having AET for a duration of between 1 and 24 months 
and group two comprised patients on AET between 25 
and 60 months. Such a division was performed as some 
researchers have indicated that breast cancer survivors 
experience more distress in the first 2  years than in the 
period between 2 and 5  years (Ploos van Amstel et  al. 
2013). Therefore, we expected that ED might be higher 
during the first 2 years of AET compared to the second 
period.
All data was analyzed using SPSS software version 
22 for Windows. The patients’ sociodemographic and 
clinical characteristics were summarized with means, 
standard deviations, ranges, and frequencies in order 
to provide a description of the sample of patients. The 
associations between sociodemographic and clinical 
variables were assessed using the Mann–Whitney U test 
and Kruskal–Wallis statistics on the data distribution. In 
cases of a significant difference among three groups, the 
Post Hoc Mann–Whitney U test was used to compare 
the three groups on dependent variables, using a Bonfer-
onni corrected p value of 0.017 to indicate statistical sig-
nificance. Relationships between ED, self-esteem, social 
support and age were examined by the Spearman prod-
uct moment correlation coefficients.
Results
Patient characteristics
Socio-demographic and medical characteristics of the 
patients are listed in Table  1. The mean age was 52.49 
(SD ± 10.30) years. Seventy-nine (75.9 %) patients were 
married, and 86 (82.7  %) had one or more children. 
Approximately two-thirds of women (66.4  %) had been 
educated at high school level or above. The majority of 
participants (70.2 %) reported their socio-economic sta-
tus as middle class. Roughly 70  % of participants had a 
BMI within the overweight or obesity category and 
more than half of women (53.8  %) were peri- or post-
menopausal. With regards to treatment, the duration of 
AET for the overall sample ranged from 1 to 58 months 
(Mean =  24.38, SD =  18.26). More than half were tak-
ing AIs (52.9 %), and the remaining women were taking 
tamoxifen (47.1  %) at the time of participation in this 
study. Before AET treatment, 71.2 % of women received 
radiotherapy and 61.5  % received chemotherapy. With 
regards to the primary breast tumor and grade, nearly 
half of the patients were reported as T2 and grade II 
(51 and 49  % respectively). Fifty-nine patients (56.7  %) 
underwent mastectomy, while the remainder had breast-
conserving surgery.
Relationship between emotional distress and patients’ 
socio‑demographic and clinical factors
Table  2 reveals that, with regards to the level of ED, 
unmarried women were significantly different from 
married women. Analysis of the two groups’ means 
indicated that the average ED score for single women 
(19.12  ±  10.47) was significantly higher than the score 
for married women (13.17  ±  7.87). A Kruskal–Wal-
lis analysis of variance indicated that the three patients’ 
education groups differed significantly on ED χ2(2, 
N =  104) =  9.49, p =  0.009. Post Hoc Mann–Whitney 
tests (using a Bonferonni corrected p value of 0.017 to 
indicate statistical significance) compared the three 
patients’ education groups. According to this analysis, 
women who completed primary or secondary school 
graduates (18.68  ±  9.57) had significantly higher ED 
compared to women who were high school graduates 
(12.38 ± 7.23) and those who had graduated from college 
or above (12.68 ± 8.43). Significant associations were not 
observed between ED and other patient characteristics 
(number of children, body mass index, menopausal sta-
tus, and socioeconomic status) and the medical variables 
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of patients (type of current treatment, duration category 
of AET used, received radiotherapy and chemotherapy, 
tumor stage, histological grade).
Relationship between self‑esteem, perceived social 
support and emotional distress
As indicated in Table  3, ED was negatively correlated 
with perceived social support (r = −0.32, p < 0.01) and 
self-esteem (r = −0.35, p  <  0.01). This means that hav-
ing greater perceived social support and self-esteem was 
related to lower ED. The age of patients was not related 
with ED (r = 0.43, p > 0.05).
Discussion
After the completion of primary treatment, patients with 
breast cancer often receive long-term AET to reduce 
disease recurrence and to improve survival; therefore, 
awareness about their psychological experiences is 
important in this long duration of treatment. For that 
reason, we designed the current study to provide a more 
detailed picture of the psychosocial characteristics of 
women undergoing AET and focused on the relationship 
between these factors and levels of ED.
Mehnert and Koch (2008) indicated that lower edu-
cation is a predictor of psychological comorbidity in 
patients with breast cancer. Conversely Gómez-Campelo 
et al. 2014 reported that having a higher educational level 
was associated with more psychological distress. In our 
study, in line with Menhert and Koch, we found that 
patients who completed primary or secondary school 
were significantly more likely to have a higher level of ED 
than those who had completed high school and college or 
above. Our findings might be explained by the fact that 
patients with higher educational levels may have more 
awareness about recent advances in treatment options 
from different sources such as the Internet, and as a 
Table 2 Distributions of  level of  psychological distress according to  medical and  sociodemographic characteristics 
of patients
MWU Mann–Whitney U, KW Kruskall Wallis
Patient characteristics % (n) HAD total mean ± SE Treatment factors n (%) HAD total mean ± SE
Marital status Current Treatment
 Married 75.9 (79) 13.17 ± 7.87 Tamoxifen 47.1 (49) 13.65 ± 8.30
 Single 24 (25) 19.12 ± 10.47 Aromatase inhibitors (AI) 52.9 (55) 15.45 ± 9.37
MWU = 704, p = 0.031 MWU = 1223, p = 0.417
Children Duration of AET
 One or More 82.7 (86) 14.36 ± 8.53 Between 1 and 24 months 49 (51) 16.01 ± 9.19
 None 17.3 (18) 15.77 ± 10.60 Between 25 and 58 months 51 (53) 13.24 ± 8.45
MWU = 761, p = 0.911 MWU = 1073, p = 0.070
Education Pathological tumor stage
 Primary or secondary 33.7 (35) 18.68 ± 9.57 T1 40.4 (42) 15.40 ± 9.28
 High school 32.7 (34) 12.38 ± 7.23 T2 51 (53) 14.30 ± 8.83
 College or above 33.7 (35) 12.68 ± 8.43 T3 8.7 (9) 12.66 ± 7.77
KW = 9.489, p = 0.009 KW = 0.589, p = 0.745
Body mass index Histological grade
 ≤24.99 31.7 (33) 12.48 ± 7.12 Grade I 11.5 (12) 12.91 ± 9.11
 25–29.9 40.4 (42) 14.33 ± 9.65 Grade II 49 (51) 15.60 ± 8.98
 ≥30 27.9 (29) 17.41 ± 9.08 Grade III 39.4 (41) 13.85 ± 8.77
KW = 4.188, p = 0.123 KW = 1.750, p = 0.417
Menopausal status Type of surgery
 Pre-menopausal 46.2 (48) 13.50 ± 8.43 Mastectomy 56.7 (59) 14.66 ± 8.76
 Peri or post-menopausal 53.8 (56) 15.55 ± 9.23 Breast conserving surgery 43.3 (45) 14.53 ± 9.14
MWU = 1194, p = 0.329 MWU = 1308, p = 0.901
Socioeconomic status Radiotherapy
 Low 17.3 (18) 16.05 ± 10.11 Yes/no 71.2 (74)/28.8 (30) 14.97 ± 8.97/13.70 ± 8.75
 Middle 70.2 (73) 14.24 ± 8.69 MWU = 1020, p = 0.520
 High 12.5 (13) 14.61 ± 8.73 Chemotherapy
KW = 0.512, p = 0.774 Yes/no 61.5 (64)/38.5 (40) 15.21 ± 9.02/13.62 ± 8.69
MWU = 1129, p = 0.314
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result have less psychological distress. However more 
research is needed to elucidate the effect of education 
on ED. In addition to level of education, we found that 
single patients reported more distress than those who 
were married. It can be speculated that married women 
may have more physical support from their spouses or 
children compared to those who are single. Physical sup-
port may be important in dealing with problems such 
as transportation, particularly when patients are having 
aggressive treatment. Married women may also be less 
exposed to stressful life situations than single women due 
to their greater financial power. Therefore, unmarried 
patients might have experienced higher ED levels. Con-
sistent with our study, Giese-Davis et  al. 2012 indicated 
that unmarried women are particularly vulnerable to 
experiencing practical and psychosocial problems while 
being married protects against such problems.
In previous studies, some researchers indicated that 
anxiety and depressive symptoms were not significantly 
affected by endocrine therapy during the first 3  years of 
treatment (Nystedt et al. 2003). In a different study, Land 
et  al. 2006 investigated symptoms of depression over a 
period of 60  months and demonstrated that the depres-
sion score remained unchanged during the entire course of 
treatment (Land et al. 2006). In our study, while the differ-
ence was not at the statistical level, we found that women 
who were taking AET revealed higher ED in their first 
2 years of treatment compared to those who were within 
the 25th to 60th months. This difference of lower ED levels 
at the late (3- to 5-year) period may be secondary to the 
fact that more time has elapsed since the initial aggressive 
treatments (i.e. surgery, chemo and radiotherapy). Future 
research is required to clarify the relationship between ED 
and duration of AET. In addition to these findings, in line 
with previous studies, our study showed no significant dif-
ference in ED score between patients treated with tamox-
ifen and those who were treated with AIs (Schilder et al. 
2009; Takei et al. 2012; Ohsumi et al. 2011).
Perceived social support has been established as pro-
tective factor, which mitigates psychological distress in 
breast cancer patients (Friedman et al. 2006). In accord-
ance with that study, our data revealed that perceived 
social support and self-esteem were negatively related 
with emotional distress. These findings also support the 
results of Brunet et  al. (2014) that perceived support 
could be one way to help patients to cope with stress. In 
the light of these studies, medical staff should identify 
patients who have low perceived social support and self-
esteem and refer them to psycho-oncology units.
Limitations
Our study has some limitations. It has a cross-sectional 
design which provides no information on causal relation-
ship. For that reason, longitudinal studies are required 
to establish more clearly the causal relationship between 
distress, patient related factors and medical charac-
teristics and future studies are also needed to examine 
mediating/moderating effects of the identified risk fac-
tors. In addition, we did not evaluate the data regarding 
the comorbidities of patients. Despite these limitations, 
our study is noteworthy because we broadly assessed the 
range of factors that related with distress along with per-
ceived social support and self-esteem.
Implications for clinical practice
Patient-reported outcomes are particularly useful in the 
setting of prevention. In this respect, outcomes of the 
present study will assist in the design of interventions to 
prevent or manage the psychological mood of patients 
with breast cancer on AET. The current findings suggest 
that professionals need to continuously assess and moni-
tor depressive and anxiety symptoms in breast cancer 
patients after initiation of AET especially if they factors 
related to high levels of ED as described above. As several 
recent studies have already identified that high distress is 
a risk factor for poorer medical adherence of AET (Cahir 
et al. 2015; Colleoni et al. 2000), our study results are of 
significance to ensure the continuation of treatment by 
detecting potential patients who may be prone to have 
higher distress in a timely fashion.
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